Skip to main content

Table 1 Characteristics of study population at baseline (N = 484)

From: Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice

Variables Darunavir/r N = 170 Atazanavir/r N = 141 Dolutegravir N = 183 p
Age* 48 (40–54) 48 (43–53) 51 (43–57) 0.008
Male sex 126 (74.1) 95 (67.4) 127 (69.4) 0.399
Caucasians 157 (92.4) 136 (96.5) 164 (89.6) 0.165
HIV risk factor 0.043
 Heterosexual 74 (43.5) 68 (48.2) 83 (45.4)  
 MSM 84 (49.4) 49 (34.8) 80 (43.7)  
 IDUs 11 (6.5) 24 (17.0) 19 (10.4)  
 Other 1 (0.6) 0 1 (0.5)  
CDC stage C 48 (28.2) 34 (24.1) 53 (29.0) 0.592
HCV positive serostatus 18 (10.6) 25 (17.7) 26 (14.2) 0.193
Nadir CD4 count (cells/μL)* 219 (64–311) 194 (62–293) 194 (64–284) 0.741
Zenith HIV-RNA (log10 copies/mL)* 4.90 (4.36–5.40) 5.02 (4.48–5.39) 4.93 (4.34–5.40) 0.687
CD4 count at baseline (cells/μL)* 617 (484–793) 616 (509–786) 630 (500–800) 0.671
Years since HIV diagnosis* 9 (5–17) 11 (4–18) 14 (8–20) < 0.001
Years on antiretroviral therapy* 8 (3–14) 7 (3–13) 12 (5–18) < 0.001
Previous virological failure 91 (53.5) 78 (55.3) 94 (51.4) 0.775
Previous M184 V resistance mutation 22 (12.9) 17 (12.1) 16 (8.7) 0.419
Years of viral suppression at baseline* 5 (2–8) 4 (2–7) 8 (4–11) < 0.001
Previous regimen: < 0.001
 2NRTI + bPI 80 (47.1) 125 (88.7) 14 (7.7)
 2NRTI + NNRTI 20 (11.8) 4 (2.8) 34 (18.6)
 2NRTI + INI 24 (14.1) 1 (0.7) 32 (17.5)
Two-drug regimen 34 (20.0) 8 (5.7) 99 (54.1)
 - Lamivudine plus bPI 32 (18.8) 8 (5.7) 89 (48.6)
 - bPI plus NNRTI, InSTI or MVC 2 (1.2) 0 (0) 6 (3.3)
 - Other regimen 0 (0) 0 (0) 4 (2.2)
Other 12 (7.1) 3 (2.1) 4 (2.2)
TDF in previous regimen 97 (57.1) 119 (84.4) 65 (35.5) < 0.001
Reasons for switch to dual regimen: < 0.001
 Simplification 86 (50.6) 100 (70.9) 57 (31.1)
 Dyslipidemia 8 (4.7) 7 (5.0) 60 (32.8)
 GI toxicity 4 (2.4) 2 (1.4) 13 (7.1)
 Liver toxicity 11 (6.5) 0 4 (2.2)
 Renal toxicity 28 (16.5) 12 (8.5) 15 (8.2)
 Bone toxicity 3 (1.8) 3 (2.1) 12 (6.6)
 CNS toxicity 1 (0.6) 0 3 (1.6)
 Other toxicity 14 (8.2) 4 (2.8) 7 (3.8)
 DDI 2 (1.2) 0 6 (3.3)
 Other 13 (7.6) 13 (9.2) 6 (3.3)
 Years on previous regimen* 2 (1–4) 3 (1–5) 2 (1–3) 0.530
Study period: < 0.001
 2008–2013 37 (21.8) 88 (62.4) 0
 2013–2014 91 (53.5) 33 (23.4) 0
 2014–2015 34 (20.0) 12 (8.5) 77 (42.1)
 2015–2017 8 (4.7) 8 (5.7) 106 (57.9)
  1. Note: bPI boosted protease inhibitor, TDF tenofovir, MVC maraviroc, GI gastrointestinal, CNS central nervous system, DDI drug-drug interaction
  2. *Continuous variables (interquantile range)